FDA, Merck and Vioxx: Putting Patient Safety First?
United States Senate Committee on Finance
Thursday, November 18, 2004, 10:00 AM
216 Hart Senate Office Building
Member Statements
Chuck Grassley
(R-IA)
(R-IA)
Max Baucus
(D-MT)
(D-MT)
Witness Testimony
Panel I
David Graham, M.D., M.P.H, Associate Director for Science, Office of Drug Safety, Center for Drug Evaluation and Research, Department of Health and Human Services, Food and Drug Administration, Washington, DC
Panel II
Gurkirpal Singh, M.D., Adjunct Clinical Professor of Medicine, Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University, Stanford, CA
Bruce Pstay, M.D., Ph.D., Professor, Medicine & Epidemiology, University of Washington, Cardiovascular Health Research Unit, Seattle, WA
Panel III
Sandra Kweder, M.D., Acting Director, Office of New Drugs, Center for Drug Evaluation and Research, Department of Health and Human Services, Food and Drug Administration, Washington, DC
Panel IV
Raymond Gilmartin, Chairman, President & Chief Executive Officer, Merck & Co., Whitehouse Station, NJ